CTNNB1 and hepatocellular carcinoma: Intriguingly, almost similar numbers of patients in group C and group O showed active β-catenin signaling (93.8% versus 86.7%), when combined and compared to the rest of HCC patients, rate of β-catenin target gene upregulation in patients who have CTNNB1 mutations (n = 31) is significantly higher than patients without them (n = 94) (Fig 2C).